Queen Mary, University of London - £55m break for bone building

A spin-off company has closed a £55 million investment deal to help develop substitutes for human bone. Joost de Bruijn of the School of Engineering and Materials Science at Queen Mary, University of London, is chief executive of Progentix Orthobiology, a company developing synthetic-bone substitutes that can help trigger and accelerate bone healing and repair. Progentix has said it has signed an investment agreement with NuVasive, a medical device firm developing products for minimally disruptive surgical treatments for the spine.